Hyperhidrosis is a clinical condition characterized by sweating more than what is considered normal due to underlying medical conditions. Hyperhidrosis treatment products such as prescription antiperspirants, botulinum toxin, iontophoresis devices help reduce excessive sweating and improve the quality of life of patients. Non-invasive treatments like botulinum toxin injections and microware ablation therapy are gaining popularity due to their effectiveness and minimal risk of side effects. The global Hyperhidrosis Treatment Market is estimated to be valued at US$ 641.54 Mn in 2023 and is expected to exhibit a CAGR of 25.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Rising adoption of non-invasive treatments: The adoption of minimally invasive and non-invasive Global hyperhidrosis treatment market Size options like botulinum toxin injections and microwave ablation therapy is growing significantly owing to advantages such as minimal downtime, lower risks of complications and higher patient satisfaction. These treatment modalities are replacing conventional invasive surgical procedures for primary focal hyperhidrosis. Growing consumer preference for procedures without risks of scarring or long recovery times is a major driver boosting the demand for non-invasive hyperhidrosis treatment devices and products.
SWOT Analysis
Strength: The hyperhidrosis treatment market has grown significantly in recent years owing to the rising awareness among patients about conditions and available treatment options.
Weakness: High costs associated with treatment procedures can limit the growth potential of the hyperhidrosis treatment market.
Opportunity: Advancements in minimally invasive procedures and the emergence of new treatment technologies present lucrative opportunities for market players.
Threats: Limitations and side effects associated with drug therapies and uncertain reimbursement policies pose challenges for the market.
Key Takeaways
The global hyperhidrosis treatment market is expected to witness high growth over the forecast period of 2023 to 2030. The market size for 2024 is projected to reach US$ 641.54 Mn.
Regional analysis: North America dominates the global hyperhidrosis treatment market currently. The region accounts for the largest share due to favorable reimbursement policies, availability of advanced treatment options, and growing awareness among patients regarding disease conditions and management. Asia Pacific is expected to grow at the fastest rate during the forecast period owing to rising healthcare expenditure, increasing patient population, and growing medical tourism in several countries.
Key players: Key players operating in the hyperhidrosis treatment market are Medtronic, Abbott, Stryker, B. Braun Melsungen AG, Boston Scientific Corp., Baxter, and OMRON Healthcare, Inc. These players are focusing on new product launches, geographical expansions, and strategic collaborations to strengthen their market presence. For instance, Medtronic offers surgical devices and equipment for hyperhidrosis procedures such as endoscopic thoracic sympathectomy.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it